title: The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes.
abstract: The dyslipidemia and insulin resistance of type 2 diabetes can be improved by aerobic exercise. The effect of 6 months supervised exercise on very low-density lipoprotein (VLDL) apolipoprotein B metabolism was investigated in patients with type 2 diabetes. Moderately obese patients (n = 18) were randomized into supervised (n = 9) and unsupervised (n = 9) exercise groups. All patients were given a training session and a personal exercise program and asked to exercise four times per week at 70% maximal oxygen uptake for 6 months. Patients in the supervised group had a weekly session with an exercise trainer. VLDL apolipoprotein (apo)B metabolism was measured with an infusion of 1-(13)C leucine before and after 6 months of the exercise program. Supervised exercise for 6 months resulted in a significant within-group decrease in percent hemoglobin A1c (P < 0.001), body fat (P < 0.004), nonesterified fatty acid (P < 0.04), and triglycerides (P < 0.05) and an increase in insulin sensitivity (P < 0.01). There was a decrease in VLDL apoB pool size (160.8 +/- 42.6 to 84.9 +/- 23.2 mg, P < 0.01) and VLDL apoB secretion rate (11.3 +/- 2.6 to 5.5 +/- 2.0 mg/kg.d, P < 0.05) with no change in fractional catabolic rate. In a between-group comparison, the decrease in VLDL apoB secretion rate in the supervised group did not achieve significance. This study demonstrates that in type 2 diabetes, a supervised exercise program reduces VLDL apoB pool size, which may be due to a decrease in VLDL apoB secretion rate.
authors.affiliation: Department of Diabetes, Endocrinology, and Internal Medicine, St. Thomas' Hospital, Guys, Kings and St. Thomas' School of Medicine, Kings College, London SE1 7EH, United Kingdom.
authors.forename: Saima
authors.initials: S
authors.lastname: Alam
authors.forename: Michael
authors.initials: M
authors.lastname: Stolinski
authors.forename: Claire
authors.initials: C
authors.lastname: Pentecost
authors.forename: Massoud A
authors.initials: MA
authors.lastname: Boroujerdi
authors.forename: Richard H
authors.initials: RH
authors.lastname: Jones
authors.forename: Peter H
authors.initials: PH
authors.lastname: Sonksen
authors.forename: A Margot
authors.initials: AM
authors.lastname: Umpleby
mesh_terms: D000328:Adult; D000368:Aged; D001055:Apolipoproteins B / Q000097:blood / Q000378:metabolism*; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D003920:Diabetes Mellitus / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D007700:Kinetics; D008055:Lipids / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009765:Obesity; D010809:Physical Fitness; D011788:Quality of Life; D013997:Time Factors
chemical_list: D001055:Apolipoproteins B; D001786:Blood Glucose; D008055:Lipids; D008079:Lipoproteins, VLDL